Colorectal cancer patients with certain genetic backgrounds may benefit more from taking aspirin to prevent cancer reoccurrence, based on a study conducted by researchers at the Baylor Scott & White Health Research Institute.

The study, published this month in Cancer Prevention Research, examined how aspirin influences the growth of cultured colorectal cancer cells with a variety of different mutational backgrounds and aimed to explain why aspirin is more effective in some patients than others. Previous studies have demonstrated that taking 600 milligrams of aspirin per day for two years resulted in a 63 percent reduction in colorectal cancer incidence.